RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2025.101339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Mengyuan Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Esophageal Squamous Cell Carcinoma, Protein Phosphatase 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fujian Provincial Health Technology Project, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
AIMS: Metastatic progression and treatment resistance determine poor prognostic outcomes of patients with esophageal squamous cellular carcinoma (ESCC), highlighting the urgent need to understand the molecular mechanisms behind this. Reticulocalbin 2 (RCN2) is a calcium-binding protein localized in the endoplasmic reticulum lumen, which mediates tumor progression in various cancer types. However, the role of RCN2 in ESCC remains unexplored. METHODS: The influence of RCN2 on ESCC progression, metastasis, and cisplatin (CDDP) resistance was assessed both in vitro and in vivo. The downstream regulatory mechanism associated with RCN2 was screened through RNA-seq, TMT 10X mass spectrometry analysis, and LC-MS/MS analysis, which was further validated through Western blot, immunoprecipitation, immunofluorescence, GST pull-down assay, and rescue experiments. RESULTS: We observed high RCN2 expression in ESCC tumor tissues from patients with metastasis, which is correlated with a higher risk of metastasis and worse survival. PPP2CA, a catalytic subunit of protein phosphatase 2 A (PP2A), and ubiquitin protein ligase E3 component N-recognin 5 (UBR5) are determined as novel RCN2 functioning interactors. Mechanistically, RCN2 facilitates PPP2CA ubiquitination and degradation dependent on the HECT domain of UBR5, thereby activating the PI3K-AKT signaling pathway. Furthermore, the activated RCN2-PPP2CA-PI3K-AKT axis is validated in clinical specimens of ESCC. Finally, targeted suppression of RCN2 synergized with CDDP treatment to prevent tumor growth and metastasis in subcutaneous and lung metastasis models. CONCLUSIONS: Overall, these findings identify RCN2 as a novel driver of ESCC metastasis and CDDP resistance. RCN2 could be a promising treatment target for ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: wang.hao@zs-hospital.sh.cn.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: guo.weigang@zs-hospital.sh.cn.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: tan.lijie@zs-hospital.sh.cn.
Förderung
- National Natural Science Foundation of China
- Fujian Provincial Health Technology Project
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Wu, M., Huang, X., Lin, M., Duan, Z., Jian, Z., You, R., Xie, P., Wu, Z., Lin, S., Zhang, S., Xu, W., Jiao, H., Tang, H., Guo, L., Wang, H., Guo, W., & Tan, L. (2026). RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101339
Vancouver
Wu M, Huang X, Lin M, Duan Z, Jian Z, You R, et al. RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101339
BibTeX
@article{Wu2026,
author = {Wu, Mengyuan and Huang, Xu and Lin, Miao and Duan, Zhiyun and Jian, Zitao and You, Runze and Xie, Peiyi and Wu, Zhiwei and Lin, Siyun and Zhang, Shaoyuan and Xu, Wenyi and Jiao, Heng and Tang, Han and Guo, Lei and Wang, Hao and Guo, Weigang and Tan, Lijie},
title = {RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2025.101339}
}
EUVIMED